-Reuters Citing Filing
Benchmark Downgrades Emergent BioSolutions to Hold
Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.
Related Posts
What’s Going On With NIO Shares Today?
NIO shares dip in premarket trading as director resigns. Recently, company disclosed January vehicle deliveries and strategic partnership announcements.
Zoom’s Pace of Innovation Is Good, But Analysts Hold Reservations Due To Competitive Landscape
Needham analyst Ryan Koontz reiterated a Hold rating on Zoom Video Communications, Inc (NASDAQ:
Robinhood’s Limited Crypto Products & Declining Trading Volume Flagged As Concerns, This Analyst Initiates With A Hold
Needham analyst John Todaro initiated coverage on Robinhood Markets Inc (NASDAQ: HOOD)